Effect of satralizumab on relapse severity in neuromyelitis optica spectrum disorder (NMOSD): results from the Phase III SAkura studies

Patients treated with satralizumab had a lower risk of severe relapse, and were less likely to require rescue therapy for a relapse compared with placebo. The number of patients with severe relapses was low, so results should be interpreted with caution.

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically

Effect of satralizumab on relapse severity in neuromyelitis optica spectrum disorder (NMOSD): results from the Phase III SAkura studies

Patients treated with satralizumab had a lower risk of severe relapse, and were less likely to require rescue therapy for a relapse compared with placebo. The number of patients with severe relapses was low, so results should be interpreted with caution.

{{assetTitle}}

Welcome to Medically

The Roche Science Hub

You are Leaving Medically

Effect of satralizumab on relapse severity in neuromyelitis optica spectrum disorder (NMOSD): results from the Phase III SAkura studies

Patients treated with satralizumab had a lower risk of severe relapse, and were less likely to require rescue therapy for a relapse compared with placebo. The number of patients with severe relapses was low, so results should be interpreted with caution.

{{assetTitle}}

Related content

Welcome to Medically

The Roche Science Hub

You are Leaving Medically

You need to have cookies enabled to save content